Alterations in Polycomb silencing are a hallmark of many cancers.3,54,55 The stringent control of Polycomb silencing by SENP3 and USP7 suggests that these enzymatic pathways may be useful targets for anti-cancer drugs. Here, SENP3 is linked to cancer.